Targeted agents indicated for autoimmune diseases

Within the autoimmune space, payers face difficult challenges in decision making. This category has non-exhaustive and non-exclusive populations, making management by indication burdensome. To further complicate the category, indications can be subdivided even further (e.g., by severity, juvenile vs. adult, etc.), increasing the complexity even more.

Market Access slide about autoimmune diseases

We’re here to support your success from clinical to commercial – and beyond.

How can we help you today?